Oxford Immunotec Global PLC (NASDAQ:OXFD) had its target price reduced by investment analysts at Cowen and Company from $22.00 to $19.00 in a research report issued on Thursday. The firm presently has an “outperform” rating on the stock. Cowen and Company’s target price would suggest a potential upside of 17.79% from the company’s previous close.

A number of other analysts have also commented on the company. BTIG Research reissued a “buy” rating on shares of Oxford Immunotec Global PLC in a research note on Thursday, May 4th. Zacks Investment Research lowered Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a research note on Wednesday, May 3rd. ValuEngine raised Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $26.00 price target on shares of Oxford Immunotec Global PLC in a research note on Thursday, August 3rd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $20.25.

Shares of Oxford Immunotec Global PLC (NASDAQ OXFD) traded down 2.29% during mid-day trading on Thursday, reaching $15.76. The company’s stock had a trading volume of 77,817 shares. Oxford Immunotec Global PLC has a 12 month low of $9.38 and a 12 month high of $19.51. The company has a 50-day moving average of $16.85 and a 200-day moving average of $15.21. The firm’s market cap is $363.68 million.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last announced its quarterly earnings results on Tuesday, August 1st. The company reported ($0.32) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.32). Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. The firm had revenue of $26.10 million for the quarter, compared to analyst estimates of $25.05 million. During the same period last year, the firm posted ($0.29) earnings per share. The business’s revenue for the quarter was up 35.9% on a year-over-year basis. On average, analysts predict that Oxford Immunotec Global PLC will post ($1.65) earnings per share for the current year.

WARNING: This piece of content was reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/17/cowen-and-company-lowers-oxford-immunotec-global-plc-oxfd-price-target-to-19-00.html.

In other Oxford Immunotec Global PLC news, CEO Peter Wrighton-Smith sold 30,000 shares of Oxford Immunotec Global PLC stock in a transaction that occurred on Wednesday, June 28th. The stock was sold at an average price of $16.06, for a total value of $481,800.00. Following the completion of the sale, the chief executive officer now directly owns 491,668 shares in the company, valued at $7,896,188.08. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Peter Edwardson sold 22,371 shares of Oxford Immunotec Global PLC stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $17.70, for a total value of $395,966.70. Following the completion of the sale, the chief operating officer now owns 102,644 shares of the company’s stock, valued at $1,816,798.80. The disclosure for this sale can be found here. Insiders have sold 126,195 shares of company stock valued at $2,073,682 over the last 90 days. 7.58% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of the company. Redmile Group LLC increased its stake in shares of Oxford Immunotec Global PLC by 7.5% in the second quarter. Redmile Group LLC now owns 2,155,949 shares of the company’s stock worth $36,263,000 after buying an additional 151,100 shares during the last quarter. AXA increased its stake in shares of Oxford Immunotec Global PLC by 52.5% in the first quarter. AXA now owns 917,468 shares of the company’s stock worth $14,212,000 after buying an additional 315,718 shares during the last quarter. Grandeur Peak Global Advisors LLC increased its stake in shares of Oxford Immunotec Global PLC by 8.3% in the first quarter. Grandeur Peak Global Advisors LLC now owns 703,378 shares of the company’s stock worth $10,895,000 after buying an additional 53,975 shares during the last quarter. Endurant Capital Management LP increased its stake in shares of Oxford Immunotec Global PLC by 3,456.1% in the first quarter. Endurant Capital Management LP now owns 570,971 shares of the company’s stock worth $8,844,000 after buying an additional 554,915 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Oxford Immunotec Global PLC by 12.4% in the second quarter. State Street Corp now owns 447,104 shares of the company’s stock worth $7,523,000 after buying an additional 49,274 shares during the last quarter. Institutional investors and hedge funds own 84.96% of the company’s stock.

About Oxford Immunotec Global PLC

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.